Outcomes of Long‐Term Absorbable Mesh Use for Ventral Hernia Repair in Immunosuppressed Patients
World Journal of Surgery · 2026
DOI: 10.1002/wjs.70609 ↗At a glance
Multizentrische Studie in World Journal of Surgery, 2026. Written by Gaëtan-Romain Joliat and 2 co-authors. Institution: Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland. Major MEDLINE topics: Hernia, Ventral, Surgical Mesh, Herniorrhaphy, Absorbable Implants. 19 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Immunosuppressed patients are more at risk of perioperative infections. In case of ventral hernia repair, the use of a long‐term absorbable mesh could potentially decrease the infectious risk in these patients. This study aimed to assess the short‐ and mid‐term outcomes of ventral hernia repair with long‐term absorbable mesh in immunosuppressed and non‐immunosuppressed patients compared with permanent mesh in non‐immunosuppressed patients.
Methods
A retrospective cohort study was conducted in two tertiary centers in France. Consecutive patients who underwent ventral hernia repair with a long‐term absorbable (poly‐4‐hydroxybutyrate, P4HB) mesh between 2017 and 2024 were included. Immunosuppression was defined as a decreased immunity level caused by a disease or medication. Outcomes of these patients were compared to non‐immunosuppressed patients who underwent ventral hernia repair with P4HB mesh and with synthetic mesh.
Results
A total of 465 patients were included: 27 in the immunosuppressed group with P4HB mesh, 232 non‐immunosuppressed patients with P4HB mesh, and 206 non‐immunosuppressed patients with synthetic mesh. Among patients with P4HB mesh, no differences in postoperative outcomes were found between the immunosuppressed and non‐immunosuppressed groups (mean follow‐up: 15 months, 95% CI 12–17). When comparing immunosuppressed patients with P4HB to non‐immunosuppressed patients with synthetic mesh, the morbidity rate was higher in immunosuppressed patients (12/27 = 44% vs. 38/206 = 18%, p = 0.002), while surgical site infection, mesh infection, or recurrence rates were similar (mean follow‐up: 19 months, 95% CI 16–23). Immunosuppression was not found as a predictor of surgical site infection (OR 5.0, 95% CI 0.7–10.0, p = 0.091).
Conclusions
Immunosuppressed patients with P4HB mesh had similar short‐ and mid‐term infectious complications to non‐immunosuppressed patients. Long‐term recurrence rates remain to be evaluated.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Lausanne, Switzerland.
- Department of General Surgery and Surgical Oncology, Centre Hospitalier Universitaire Lyon Sud, Pierre-Bénite, France.
- Department of General and Digestive Surgery, Hautepierre Hospital, Strasbourg, France.
ORCID profiles: Gaëtan-Romain Joliat, Benoit Romain, Guillaume Passot
Cite
APA
Joliat, G. R., Romain, B., & Passot, G. (2026). Outcomes of Long‐Term Absorbable Mesh Use for Ventral Hernia Repair in Immunosuppressed Patients. World Journal of Surgery. https://doi.org/10.1002/wjs.70609
Vancouver
Joliat GR, Romain B, Passot G. Outcomes of Long‐Term Absorbable Mesh Use for Ventral Hernia Repair in Immunosuppressed Patients. World Journal of Surgery. 2026. doi:10.1002/wjs.70609
BibTeX
@article{Joliat2026,
author = {Joliat, Gaëtan-Romain and Romain, Benoit and Passot, Guillaume},
title = {Outcomes of Long‐Term Absorbable Mesh Use for Ventral Hernia Repair in Immunosuppressed Patients},
journal = {World Journal of Surgery},
year = {2026},
doi = {10.1002/wjs.70609}
}
EUVIMED